Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Immunoassays

Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults

Werner C. Albrich, Michael W. Pride, Shabir A. Madhi, Jan Callahan, Peter V. Adrian, Roger French, Nadia van Niekerk, Shite Sebastian, Victor Souza, Jean-Noel Telles, Glaucia Paranhos-Baccalà, Kathrin U. Jansen, Keith P. Klugman
Yi-Wei Tang, Editor
Werner C. Albrich
aRespiratory and Meningeal Pathogens Research Unit/Medical Research Council, Johannesburg, South Africa
fDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Pride
cPfizer Vaccine Research and Development, Pfizer Inc., Pearl River, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shabir A. Madhi
aRespiratory and Meningeal Pathogens Research Unit/Medical Research Council, Johannesburg, South Africa
bNational Institute for Communicable Diseases, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Callahan
eCallahan Associates Inc., La Jolla, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter V. Adrian
aRespiratory and Meningeal Pathogens Research Unit/Medical Research Council, Johannesburg, South Africa
bNational Institute for Communicable Diseases, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger French
dBiotechnology Clinical Development Statistics, Pfizer Inc., Pearl River, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia van Niekerk
aRespiratory and Meningeal Pathogens Research Unit/Medical Research Council, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shite Sebastian
cPfizer Vaccine Research and Development, Pfizer Inc., Pearl River, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Souza
cPfizer Vaccine Research and Development, Pfizer Inc., Pearl River, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Noel Telles
hEmerging Pathogens Laboratory, Fondation Mérieux, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glaucia Paranhos-Baccalà
hEmerging Pathogens Laboratory, Fondation Mérieux, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin U. Jansen
cPfizer Vaccine Research and Development, Pfizer Inc., Pearl River, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith P. Klugman
aRespiratory and Meningeal Pathogens Research Unit/Medical Research Council, Johannesburg, South Africa
bNational Institute for Communicable Diseases, Johannesburg, South Africa
gHubert Department of Global Health and Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Wei Tang
Memorial Sloan-Kettering Cancer Center
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.01573-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A serotype-specific urinary antigen detection (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool for pneumococcal pneumonia. We aimed to assess the diagnostic accuracy of the UAD in HIV-infected South African adults. Urine specimens from a well-defined cohort of HIV-infected South African adults with pneumonia were evaluated retrospectively in the UAD assay. Pneumonia was considered pneumococcal if either sputum Gram stain, sputum culture, blood culture, or the immunochromatographic (ICT) BinaxNow S. pneumoniae test (composite diagnostic) was positive. Among 235 enrolled pneumonia patients, the UAD assay was more frequently positive (104 [44.3%]) than the composite diagnostic (71 [30.2%]; P < 0.001) and increased the pneumococcal etiology from 30.2% by an additional 22.6% to 52.8%. The UAD assay detected more pneumococcal etiologies (45.0%) than the serotype-independent ICT (23.4%, P < 0.001). UAD identified 6/7 patients with PCV13 serotype bacteremia without misclassification of bacteremia episodes due to non-PCV13 serotypes. UAD was positive for 5.1% of asymptomatic HIV-infected persons, with higher rates among those with nasopharyngeal carriage. Concordance between serotypes identified by UAD and by Quellung reaction and PCR serotyping was 70/86 (81.4%). UAD identified the dominant serotype in multiple serotype carriage. This study confirms the utility of the UAD assay for HIV-infected adults comparing favorably with other diagnostic tests. A highly valent UAD may become a new standard for detection of pneumococcal pneumonia in adults. Prior to PCV introduction, at least 53% of pneumonia cases were due to pneumococci in HIV-infected South African adults.

INTRODUCTION

Streptococcus pneumoniae remains a leading cause of community-acquired pneumonia (CAP) (1–9), with a substantially increased burden in HIV-infected individuals in sub-Saharan Africa (10–12). The incidence of invasive pneumococcal disease (IPD) is 10 to 35 times higher than in age-matched HIV-uninfected persons, even after the introduction of pneumococcal conjugate vaccines (PCVs) (13, 14). Nevertheless, pneumococcal diagnoses in patients with CAP seem to be declining, which may be related to a true decline due to secular changes, successful pediatric vaccination programs (14–16), and declining emphasis on microbiological diagnostics (4).

The diagnosis of pneumococcal pneumonia is hampered by the lack of a diagnostic gold standard (17). Blood culture is insufficiently sensitive (18–22). Obtaining sputum is sometimes difficult, and distinguishing between colonization and infection by Gram stain and culture can be challenging. The urinary immunochromatographic BinaxNow S. pneumoniae test (ICT) for the pneumococcal C-polysaccharide is affected by pneumococcal nasopharyngeal (NP) carriage and therefore not clinically useful for children, who have a high prevalence and density of NP carriage (23). In a meta-analysis in adults, the ICT had a high specificity, 94%, but its sensitivity was only 74% (24). Pneumococcal diagnosis is clinically important, as it allows antibiotic de-escalation (25, 26). In addition, serotype-specific surveillance after PCV introduction is needed to assess success of vaccine programs and detection of serotype replacement.

Recently, a novel serotype-specific urinary antigen detection (UAD) assay was developed to evaluate the efficacy of PCV13 in adults in the CAPiTA study (22, 27). This assay detects the PCV13 serotypes and was clinically validated using urine specimens from adult patients with CAP in the Netherlands, with an overall sensitivity and specificity of 97.1% and 100% (27). In this study, we aimed to assess the diagnostic accuracy of the UAD assay in a cohort of HIV-infected South African adults with CAP who were well characterized by traditional microbiological and molecular diagnostic tests. We determined the value of the UAD assay both as a diagnostic for pneumococcal pneumonia and as a serotyping tool.

(This work has been presented in part at the 9th International Symposium on Pneumococci and Pneumococcal Diseases [ISPPD] in Hyderabad, India, 9 to 13 March 2014.)

RESULTS

We enrolled all 235 HIV-infected patients with radiologically confirmed pneumonia and 297 HIV-infected outpatient controls who had a urine specimen available for UAD. No enrolled subject had previously been vaccinated with any pneumococcal vaccine. Demographic data of the enrolled cases and controls were previously reported (20).

Establishment of positivity cutoff limits.To maintain the high level of assay specificity of the UAD assay in the HIV-infected South African study cohort, the method of nonparametric tolerance was applied to the cohort of asymptomatic HIV-infected controls (n = 297) as previously described (27). As shown in Table 1, for this study population, the original cutoffs were maintained for five (3, 4, 5, 6A, and 7F) and revised for the remaining eight PCV13 serotypes (1, 6B, 9V, 14, 18C, 19A, 19F, and 23F). Of these eight PCV13 serotypes, the cutoffs for serotypes 14, 18C, and 23F were adjusted to ensure that the revised cutoffs were within the validated assay limits, resulting in specificities of 95.5%, 96%, and 97%, respectively.

View this table:
  • View inline
  • View popup
TABLE 1

UAD assay serotype-specific cutoffs

Performance of UAD in relation to bacteremia.Among 235 blood cultures drawn, 19 (8.1%) were positive by the BacTAlert FAN aerobic test, of which 7 were positive for PCV13 serotypes as determined by Quellung reaction from blood (serotypes 14 [n = 4], 3 [n = 1], 6A [n = 1], and 6B [n = 1]), 3 were positive for non-PCV13 serotypes (17B, 22, and 25) and 9 cultures indicated growth but failed to identify an organism. The UAD assay correctly identified the serotypes of 6 of 7 cases with a PCV13 serotype bacteremia (85.7%) and was negative for a single serotype 14 isolate; in this patient, the whole-blood (WB) lytA PCR was also negative. The UAD assay was also negative for urine samples from all 3 subjects with a corresponding blood culture positive for non-PCV13 serotypes. Thus, compared to blood culture results, the UAD assay had a sensitivity of 85.7% and a specificity of 100%. Among the 28 CAP patients with pneumococcal bacteremia (as detected by positive blood culture) and/or DNAemia (as detected by positive WB lytA real-time PCR [RT-PCR]) due to a PCV13 serotypes, the UAD was positive for 25 (89.3%).

All of the 9 patients whose blood cultures indicated growth but failed to identify an organism were subsequently determined to be positive for pneumococcus via latex agglutination or nested PCR analysis. Urine samples from all of these subjects were positive in the UAD assay for a PCV13 serotype (serotypes 14 [n = 2], 1 [n = 2], 3 [n = 1], 4 [n = 1], 18C [n = 1], and 19A [n = 2]). For 4 of these 9 patients a serotyping PCR was available from WB, and classification of all 4 was in agreement with the UAD assay result (n = 1 for each of serotypes 1, 3, 14, and 19A). For 8 of these 9 patients, a serotyping PCR (for the PCV13 serotypes) from a nasopharyngeal swab (NPS) was available: 5 (62.5%) of these 8 had an identical serotype in NPS and by the UAD assay (serotypes 1 [n = 2], 3 [n = 1], 4 [n = 1], and 19A [n = 1]); 1 patient had a discrepancy (serotype 19A in UAD assay and serotype 19F in PCR from NPS), and for 2 patients, the UAD assay showed PCV13 serotypes (14 and 18C), while the serotyping PCR from NPS did not detect a serotype.

Performance of the UAD assay compared to other pneumococcal diagnostics.For 222 CAP patients, both the UAD assay and urine ICT were performed on admission urine. The urine ICT was positive for 52 (23.4%) patients. Of these, 40 (76.9%) had a positive UAD (see Table S1 in the supplemental material). The UAD assay identified 60 additional cases when the urine ICT was negative and was more frequently positive than the urine ICT (45.0%; P < 0.001). Combining urine ICT and UAD assay resulted in attribution of CAP in 50.5% of patients to pneumococcus.

If restricted to the PCV13 serotypes (identified with serotyping PCR in WB or Quellung reaction from blood), the sensitivity of the UAD assay in relation to the urine ICT was 100% (17/17). The UAD assay was positive for 7 patients with negative ICT, and both assays were negative for 3 patients. The sensitivity of the UAD assay was higher (88.9% [24/27]) than that of the ICT (63.0% [17/27]) in relation to bacteremia and/or DNAemia due to a PCV13 serotype (P = 0.03).

Among patients with PCV13 serotype bacteremia and/or DNAemia, the UAD assay was positive for 20 (90.9%) of 22 patients with a pneumococcal NP colonization density of ≥8,000 copies/ml (a surrogate for diagnosis of pneumococcal pneumonia [20]) and for all 3 patients with low NP pneumococcal colonization density (<8,000 copies/ml) (see Table S1). Among patients with identification of PCV13 serotype from any specimen (blood, sputum, nasopharyngeal specimen, or oropharyngeal specimen), the UAD was positive for 74.7% (62/83) of patients with an NP colonization density of ≥8,000 copies/ml and for 52.2% (12/23) of patients with an NP colonization density of <8,000 copies/ml (P = 0.047).

The UAD assay was more frequently positive than the composite diagnostic (104/235 [44.3%] versus 71/235 [30.2%]; P < 0.001 [Table 2]). Based on this composite diagnostic, the sensitivity of the UAD was 71.8% (51/71) and 84.9% (45/53) if restricted to the PCV13 serotypes identified from any specimen (blood, sputum, nasopharyngeal specimen, or oropharyngeal specimen). Combining UAD assay and composite diagnostic resulted in a pneumococcal diagnosis in 124 (52.8%) patients, which was higher than the composite diagnostic alone (P < 0.001) but not statistically different from the UAD assay alone (P = 0.07). Adding the UAD assay to an extended composite diagnostic (composite diagnostic or WB lytA RT-PCR positive or lytA RT-PCR from NPS with ≥8,000 copies/ml) resulted in 158 (67.2%) patients being shown to have pneumococcal etiology (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

Diagnostic performance of the UAD assay in relation to composite diagnostics

Serotype distribution and concordance with other serotyping methods.The UAD assay identified 2 PCV13 serotypes in 12 patients and 3 serotypes in 2 patients. The serotypes identified by the UAD assay were concordant with the serotypes detected by serotyping PCR and Quellung reaction in 70 patients and were different in 16 patients (Table 3).

View this table:
  • View inline
  • View popup
TABLE 3

Serotype discrepancies based on Quellung and PCR-based serotyping methodologies compared to UAD assay in pneumonia patientsa

In 11 of 15 patients with concordant serotypes and >1 serotype in blood or the nasopharynx, the UAD assay serotype correlated with the dominant serotype, i.e., the serotype with highest copy number. In 3 of 15 patients, the UAD assay identified not the dominant of two serotypes but the serotype which was consistently identified in other specimens and also by Quellung reaction. The remaining patient had serotypes 1 and 18C identified by UAD, while serotyping PCR detected serotypes 7F (106copies/ml), 1 (400 copies/ml), and 18C (170 copies/ml) from NPS and serotype 1 from NW.

Lack of correlation of colonization density and UAD in CAP.Serotype-specific quantitative NP colonization densities, as measured with serotyping RT-PCR, were correlated with quantitative UAD values separately for each serotype in pneumonia patients. When restricted to only those patients whose UAD values were within the linear assay range for each serotype, there was no significant correlation for any serotype (Table 4).

View this table:
  • View inline
  • View popup
TABLE 4

Correlation between colonization density (serotyping RT-PCR from NP swab) and quantitative UAD result in pneumonia patientsa

Performance of UAD assay for asymptomatic HIV-infected South African controls.PCR serotyping from NPS and UAD results were collected from 297 asymptomatic HIV-infected South African controls. UAD was positive for 15 controls (5.1% [Table 5]), 9 without pneumococcal NP carriage and 6 with the corresponding PCV13 serotype identified by serotyping PCR from NPS. There were 33 controls with PCV13 serotype carriage, of whom 6 had a corresponding serotype in the UAD assay (18.2%). Of 238 controls without pneumococcal carriage, UAD was less frequently positive (n = 9) than in controls with identified carriage (P = 0.005). In addition, the only control person who had a positive urine ICT also had a negative UAD result, and there was no evidence of NP carriage by culture or lytA RT-PCR.

View this table:
  • View inline
  • View popup
TABLE 5

UAD in asymptomatic controls

DISCUSSION

In this study, the UAD assay was successfully adapted to be used in a cohort of HIV-infected South African adults with pneumonia and proved to be a diagnostic test of high accuracy. There was good correlation with serotypes identified by Quellung reaction from bacteremic patients. UAD demonstrated high specificity and sensitivity in bacteremic patients and detected 15 times more PCV13 serotype infections than blood cultures, 4 times more than blood cultures and WB lytA PCR combined, and twice as many as the commercial urine ICT. The UAD assay detected an additional 23% of cases beyond currently available standard pneumococcal tests, resulting in an overall pneumococcal etiologic fraction of 53%. UAD was more frequently positive for asymptomatic controls with pneumococcal carriage, but UAD values did not correlate with colonization density.

The UAD assay demonstrated very good sensitivity and specificity, 89% and 100%, respectively, and outperformed the urine ICT, which was positive for only 4 of 7 patients with PCV13 serotype bacteremia. The UAD assay was developed to detect pneumococcal pneumonia due to a PCV13 serotype irrespective of the presence of bacteremia (27, 28). As a limit assay with either a positive or a negative result, positivity cutoff values were originally derived from urine samples obtained from an adult population with no clinical suspicion of CAP. These cutoff values for serotype-specific pneumococcal polysaccharides ranged between 1.7 and 330.5 U/ml (27). The UAD assay was recently suspected to yield false-positive results for several adults with pneumonia from whom the urine was collected shortly after receipt of the 23-valent pneumococcal polysaccharide vaccine(29). As detailed by Pride et al. (27), to avoid false positives, it is important that the UAD assay results take into account clinical and radiological findings at the time of urine specimen collection. The suitability of the UAD assay should be first evaluated in the intended study population (27). Consistent with these recommendations and to maintain the high specificity of the UAD assay in our study population, we first evaluated the appropriateness of the established UAD cutoffs by examining asymptomatic HIV-infected adults without history of a respiratory tract infection within the last 30 days.

A relatively high positivity rate (∼13% [data not shown]) was observed with the established CAPiTA cutoffs in the HIV-infected controls, resulting in an overall UAD assay specificity of 89% for this population. The main reason for the necessity to change some of the cutoff values was likely the higher carriage rate in our asymptomatic cohort, which was similar to previously reported carriage rates in Soweto, South Africa (30), compared to the likely considerably lower carriage prevalences in European and North American adults (31, 32) that were used to establish the CAPiTA cutoffs. To account for the higher carriage rate in this cohort and to improve the specificity of the UAD assay, cutoffs were adapted based on previously used methodology (27), using urine specimens from our controls. The overall UAD assay specificity increased from 89% to at least 95% with the adapted cutoffs. The 100% specificity of the UAD assay in relation to bacteremia allows the extrapolation of these findings to patients with nonbacteremic pneumococcal pneumonia. While the urine ICT is serotype independent and should therefore identify all pneumococcal episodes, UAD was twice as frequently positive as the ICT (45% versus 23%) in patients with bacteremic and nonbacteremic CAP. The observed sensitivity of the urine ICT in this study falls in the lower range of reported pooled sensitivities of 68 to 74% (with ranges from 29% to 87%) in recent meta-analyses in HIV-uninfected persons (24, 33). Sensitivities of the urine ICT are similar for HIV-infected and HIV-uninfected adults (24) and higher for bacteremic patients (34, 35). The UAD assay was 100% sensitive in relation to the ICT if restricted to patients with PCV13 serotype bacteremia. Irrespective of any serotype, UAD was significantly more frequently positive than a predefined pneumococcal composite diagnostic of blood culture, sputum culture and Gram stain, and urine ICT. Adding the UAD to the composite diagnostic increased the presumed pneumococcal etiology up to 52.8% (75% relative increase in etiology). Since the UAD assay was positive in 89% (25/28) of PCV13 serotype bacteremias and/or DNAemia and only 63% (38/60) of episodes of bacteremia and/or DNAemia were due to a PCV13 serotype, we extrapolate that 78% of pneumonia episodes in this South African cohort of HIV-infected adults might be pneumococcal. This is close to proportions which were reported in the 1930s (4, 36, 37) and considerably higher than contemporary pneumococcal proportions (18), which vary from 5% (38) to 57% (7). Few recent comprehensive etiology studies with African adults are available. In Kenya, 46% of adult pneumonias were pneumococcal (1, 39). Importantly, our cohort was recruited prior to the introduction of PCV7/13 into the South African pediatric vaccine schedule. South African, UK, and U.S. data reproducibly showed that pediatric PCV reduced IPD in adults (14–16), and U.S. surveillance revealed a decrease of all-cause pneumonia in adults (40). Thus, our data likely represent maximum pneumococcal proportions in adults prior to the introduction of childhood PCVs.

In some cases, the serotype declared by the UAD assay was different from the carriage serotype. Since, similar to our results, the serotype identified by the UAD assay had been shown in a previous study to correlate 100% with the serotypes from blood cultures in patients with bacteremic CAP (27), alternative explanations need to be considered for the discrepancy from carriage serotypes, not taking into account the possibility of technical error or mislabeling (41). This finding might reflect a previous infection rather than an incorrect detection of the carriage serotype. If pneumonia is due to an invasive serotype such as 1, 4, and 5, which are rarely carried or carried at low densities in the NP, these serotypes might be missed with NP sampling (42, 43). In contrast, in a longitudinal study of pneumococcal carriage and infection in U.S. infants, the infecting serotype was detected in the nasopharynx in all 31 infants at the time of infection (44). The commercially available urine ICT can remain positive for months after infection (45), but this period is still unknown for the UAD. With molecular serotyping assays, the proportion of multiple serotype carriage has increased in comparison to conventional techniques (46, 47). Quantitative PCR furthermore allows identification of a predominant serotype with the highest colonization density (47, 48). In patients with multiple serotype carriage and bacteremic and/or DNAemic pneumococcal pneumonia, the dominant carriage serotype usually correlated with the serotype identified in WB, as recently reported for this cohort (48). Accordingly, the UAD assay usually correlated with either the dominant carriage serotype or the serotype most consistently identified from other specimens or from blood.

Among controls, pneumococcal NP carriage was associated with a 4-fold risk of a positive UAD. This association was previously shown for the commercial urine ICT for children, but not adults, which therefore lacks utility for children (23). No data on the performance of the UAD assay for children has been published yet. Alternatively, positive UAD in controls might result from undocumented pneumococcal infection more than 30 days prior to specimen collection. More data are required on the duration of positivity of the UAD assay and the role of NP carriage. However, even if a 5% false-positivity rate related to carriage in asymptomatic persons will be confirmed in future studies, given a 50% proportion of pneumococcus among pneumonia episodes, with 85% sensitivity and 95% specificity the ratio of true-positive to false-positive UAD would be 17:1, rendering the UAD assay highly useful for HIV-infected patients with pneumonia to diagnose pneumococcal pneumonia while at the same time providing information on the presence of the PCV13 serotypes. It is therefore useful in the clinical setting as well as for epidemiological and research studies. In contrast, for asymptomatic controls—who may have only a 0.1% risk of developing pneumococcal pneumonia annually—the UAD would lead to 50 times more false-positive than true-positive results, rendering this assay a poor diagnostic test for asymptomatic persons; however, the UAD assay was not designed for this purpose.

The main strength of this study is that it was performed in a well-characterized patient cohort with extensive pneumococcal testing from a large number of specimens. Thus, the utility of the UAD assay can be extended to South African HIV-infected adults with some adaptations of the cutoff values. It also can be considered a proof of concept study of how to adjust cutoff values. The high sensitivity and specificity and the resulting proportion of pneumococcal etiology approaching historic figures support our findings.

The main limitations are that this was a retrospective single-center study with relatively few patients with bacteremic pneumococcal pneumonia and the limited number of cohort-matched controls. As discussed above, due to the unknown duration of positivity, our data are not able to conclusively distinguish carriage from recent infection. Since adjustments of the positivity cutoffs were necessary in order to maintain the high specificity, reevaluation of cutoffs is advisable when this assay is introduced for use in evaluating other populations which have not been studied yet. Addition of nonvaccine serotypes would be useful to study serotype replacement after vaccine implementation and thus provide information which serotypes should be included in novel vaccine formulations.

In conclusion, our data confirm the high diagnostic accuracy of the UAD assay as a research tool to detect pneumococcal pneumonia with simultaneous determination of PCV13 serotypes in HIV-infected South African adults after slight adaptation of cutoff values. Therefore, the UAD also allows determining direct and indirect effects of vaccination programs on adult pneumococcal infections. Our data support further evaluation of expanded-serotype UAD assays, which may become a new standard for detection of pneumococcal pneumonia in adults. Information on duration of positivity, effects of carriage, and utility in children is urgently needed.

MATERIALS AND METHODS

Patients.Adult patients hospitalized with radiologically confirmed CAP at Chris Hani Baragwanath Hospital, Soweto, South Africa, were enrolled between 2005 and 2007, prior to introduction of PCV7 (2009) and PCV13 (2011) into the national pediatric vaccination schedule (20). This analysis was restricted to HIV-infected persons. HIV-infected adult outpatients without signs of respiratory infection were enrolled as controls.

Specimen collection and microbiological methods.A single aerobic FAN blood culture (BacT Alert FAN aerobic using 10 ml of blood), Gram stain, and cultures of induced sputum, urine, oropharyngeal and NP swabs (OPS and NPS) were obtained on admission as previously reported (Fig. 1.) (20). Nasal washes (NW) were performed by reaspiration after applying 4 ml of 0.9% NaCl. Quantitative lytA real-time PCR (RT-PCR) was performed on NP swabs (20) and Fast-track Diagnostic respiratory 21-plus test (Fast-track Diagnostics) for 19 respiratory viruses and 5 bacteria on NW. Whole blood (WB) was tested with an in-house triplex RT-PCR for pneumococcus (lytA), Haemophilus influenzae type b, and Staphylococcus aureus (49). Urine was tested with the ICT within 12 h (BinaxNow S. pneumoniae test). Remaining urine was stored at −20°C prior to further processing.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Diagnostic flow in pneumonia patients and controls. UAD, serotype-specific urinary antigen detection assay; ICT, immunochromatographic BinaxNow S. pneumoniae test. Boxes with bold frame include assays in pneumonia patients and controls; regular-frame boxes include assays limited to pneumonia patients.

Serotype-specific UAD assay.The urinary antigen detection (UAD) assay is a noncommercial Luminex technology-based multiplex serotype-specific assay that utilizes spectrally unique microspheres coated individually with serotype-specific antipneumococcal polysaccharide monoclonal antibodies (capture antibodies) capable of detecting the following serotypes: 1, 3, 4, 5, 6A/C, 6B, 7F/A, 9V/A, 14, 18 (C, A, B, and F), 19A, 19F, and 23F (22, 27). For the UAD assay, positivity cutoff limits, based on antigen concentrations read off a standard curve, were established for each serotype using 400 control urine specimens obtained from subjects ≥50 years of age in the Netherlands and United States without clinical suspicion of CAP in the 2 months prior to obtaining the urine sample. Nonparametric tolerance intervals were computed from these concentrations, giving a range predicted to contain 98% of negative urine samples with 99% confidence, thus achieving at least 97% assay specificity for each serotype. For each serotype the cutoff was based on the second highest control sample concentration (except for serotypes 1 and 5, for which the highest UAD value was used). These positivity cutoff values were clinically validated in a pilot study in the Netherlands prior to use in the CAPiTA study (27, 28).

The suitability of the established cutoff values were evaluated for use in this study cohort (HIV-infected South African adults with CAP) and adjusted, if needed, using similar nonparametric methods on the 297 asymptomatic HIV-infected South African control specimens to achieve ≥95.5% assay specificity for each serotype. To be conservative, it was agreed that the existing cutoffs would not be lowered. If a positivity cutoff needed to be increased, it was set to the second highest urine value from among the asymptomatic HIV-infected South African controls. If a proposed cutoff based on the second highest value was above the upper limit of the assay's validated range, the cutoff was based on the highest control urine value that was still within the validated assay range.

Diagnostic criteria for pneumonia.Pneumonia was considered pneumococcal if any of the composite diagnostic criteria were positive: blood culture, good-quality (>25 neutrophils and <10 epithelial cells per low-power field) sputum Gram stain or culture (20), or urine ICT.

Serotyping.Serotyping of all isolated pneumococci was performed using the Quellung method. No attempt was made to identify multiple serotypes; i.e., a single Quellung reaction for serotyping was performed per visually appreciated colony morphology. We also performed 13 serotype-specific PCRs for the PCV13 serotypes from NPS and from sputa if one-step duplex lytA PCR (20) was highly positive (lytA threshold cycle [CT] ≤ 35). Serotyping PCR from NW and WB was performed by a quantitative multiplex RT-PCR for 40 pneumococcal serotypes, including all PCV13 serotypes (Fig. 1) (48).

The serotypes identified by UAD and by serotyping PCR and Quellung reaction were compared. If there was ≥1 serotype which was identified both by UAD and by any other method from any specimen (NPS with PCR and Quellung; NW with PCR, OPS with Quellung; sputum with PCR and Quellung; blood with PCR and Quellung), the result was judged concordant. Results were judged discordant if one or more PCV13 serotypes identified by UAD were different from all results identified by PCR serotyping or Quellung reaction. UAD specimens positive for >2 serotypes were considered indeterminate in previous studies, but for the purpose of this analysis all serotypes above the serotype-specific cutoff values were reported. While UAD results are usually provided as positive, negative, or indeterminate, the calculated UAD value (serogroup-specific S. pneumoniae polysaccharide [PnPS] units per milliliter) for a sample was used to test whether there was a correlation with NP colonization density from the same subject.

Statistical methods.Proportions were compared with Pearson's χ2 test or Fisher's exact test, as appropriate. Correlations between continuous variables were assessed by Spearman's correlation coefficient (r). P values were considered statistically significant if they were ≤0.05.

This study was approved by the ethics committees of the University of the Witwatersrand and Emory University. Informed consent was provided by all patients and controls.

ACKNOWLEDGMENTS

W.C.A. received an honorarium from GlaxoSmithKline (GSK) and support from BRAHMS Thermo Fisher and bioMérieux to attend meetings and fulfilled speaking engagements. S.A.M. received research funding and honoraria from Pfizer vaccines and GSK and institutional grant support from Wyeth. K.P.K. received consulting and research funding from Pfizer Vaccines and consulting funding from GSK. M.W.P., R.F., S.S., V.S., and K.U.J. are employees of Pfizer Inc.

We thank Pfizer for performing the lytA RT-PCR and Binax for supplying ICT, BinaxNow Streptococcus pneumoniae, free of charge.

This work was supported by Centers for AIDS Research (CFAR) National Institutes of Health (NIH) grant P30 A1050409 to K.P.K.

The funding source had no influence on data analysis, the draft of the manuscript, or the decision to submit the manuscript for publication.

FOOTNOTES

    • Received 20 July 2016.
    • Returned for modification 10 August 2016.
    • Accepted 2 November 2016.
    • Accepted manuscript posted online 9 November 2016.
  • Supplemental material for this article may be found at https://doi.org/10.1128/JCM.01573-16 .

  • Copyright © 2016 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Scott JA,
    2. Hall AJ,
    3. Muyodi C,
    4. Lowe B,
    5. Ross M,
    6. Chohan B,
    7. Mandaliya K,
    8. Getambu E,
    9. Gleeson F,
    10. Drobniewski F,
    11. Marsh K
    . 2000. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet355:1225–1230. doi:10.1016/S0140-6736(00)02089-4.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Howard LS,
    2. Sillis M,
    3. Pasteur MC,
    4. Kamath AV,
    5. Harrison BD
    . 2005. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect50:107–113. doi:10.1016/j.jinf.2004.05.003.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Johansson N,
    2. Kalin M,
    3. Tiveljung-Lindell A,
    4. Giske CG,
    5. Hedlund J
    . 2010. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis50:202–209. doi:10.1086/648678.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Bartlett JG
    . 2011. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis52(Suppl 4):S296–S304. doi:10.1093/cid/cir045.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Welte T,
    2. Torres A,
    3. Nathwani D
    . 2012. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax67:71–79. doi:10.1136/thx.2009.129502.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Musher DM,
    2. Roig IL,
    3. Cazares G,
    4. Stager CE,
    5. Logan N,
    6. Safar H
    . 2013. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect67:11–18. doi:10.1016/j.jinf.2013.03.003.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Karhu J,
    2. Ala-Kokko TI,
    3. Vuorinen T,
    4. Ohtonen P,
    5. Syrjala H
    . 2014. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis59:62–70. doi:10.1093/cid/ciu237.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Holter JC,
    2. Muller F,
    3. Bjorang O,
    4. Samdal HH,
    5. Marthinsen JB,
    6. Jenum PA,
    7. Ueland T,
    8. Froland SS,
    9. Aukrust P,
    10. Husebye E,
    11. Heggelund L
    . 2015. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis; 15:64. doi:10.1186/s12879-015-0803-5.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Menzies RI,
    2. Jardine A,
    3. McIntyre PB
    . 2015. Pneumonia in elderly Australians: reduction in presumptive pneumococcal hospitalizations but no change in all-cause pneumonia hospitalizations following 7-valent pneumococcal conjugate vaccination. Clin Infect Dis61:927–933. doi:10.1093/cid/civ429.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Feikin DR,
    2. Feldman C,
    3. Schuchat A,
    4. Janoff EN
    . 2004. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis4:445–455. doi:10.1016/S1473-3099(04)01060-6.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Janoff EN,
    2. Breiman RF,
    3. Daley CL,
    4. Hopewell PC
    . 1992. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med117:314–324.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Klugman KP,
    2. Madhi SA,
    3. Feldman C
    . 2007. HIV and pneumococcal disease. Curr Opin Infect Dis20:11–15. doi:10.1097/QCO.0b013e328012c5f1.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Heffernan RT,
    2. Barrett NL,
    3. Gallagher KM,
    4. Hadler JL,
    5. Harrison LH,
    6. Reingold AL,
    7. Khoshnood K,
    8. Holford TR,
    9. Schuchat A
    . 2005. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis191:2038–2045. doi:10.1086/430356.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. von Gottberg A,
    2. de Gouveia L,
    3. Tempia S,
    4. Quan V,
    5. Meiring S,
    6. von Mollendorf C,
    7. Madhi SA,
    8. Zell ER,
    9. Verani JR,
    10. O'Brien KL,
    11. Whitney CG,
    12. Klugman KP,
    13. Cohen C
    . 2014. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med371:1889–1899. doi:10.1056/NEJMoa1401914.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Moore MR,
    2. Link-Gelles R,
    3. Schaffner W,
    4. Lynfield R,
    5. Lexau C,
    6. Bennett NM,
    7. Petit S,
    8. Zansky SM,
    9. Harrison LH,
    10. Reingold A,
    11. Miller L,
    12. Scherzinger K,
    13. Thomas A,
    14. Farley MM,
    15. Zell ER,
    16. Taylor TH Jr,
    17. Pondo T,
    18. Rodgers L,
    19. McGee L,
    20. Beall B,
    21. Jorgensen JH,
    22. Whitney CG
    . 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the U S A: analysis of multisite, population-based surveillance. Lancet Infect Dis15:301–309. doi:10.1016/S1473-3099(14)71081-3.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Waight PA,
    2. Andrews NJ,
    3. Ladhani SN,
    4. Sheppard CL,
    5. Slack MP,
    6. Miller E
    . 2015. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis15:535–543. doi:10.1016/S1473-3099(15)70044-7.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Klugman KP,
    2. Madhi SA,
    3. Albrich WC
    . 2008. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis47(Suppl 3):S202–S206. doi:10.1086/591405.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Said MA,
    2. Johnson HL,
    3. Nonyane BA,
    4. Deloria-Knoll M,
    5. O'Brien KL,
    6. Andreo F,
    7. Beovic B,
    8. Blanco S,
    9. Boersma WG,
    10. Boulware DR,
    11. Butler JC,
    12. Carratala J,
    13. Chang FY,
    14. Charles PG,
    15. Diaz AA,
    16. Dominguez J,
    17. Ehara N,
    18. Endeman H,
    19. Falco V,
    20. Falguera M,
    21. Fukushima K,
    22. Garcia-Vidal C,
    23. Genne D,
    24. Guchev IA,
    25. Gutierrez F,
    26. Hernes SS,
    27. Hoepelman AI,
    28. Hohenthal U,
    29. Johansson N,
    30. Kolek V,
    31. Kozlov RS,
    32. Lauderdale TL,
    33. Marekovic I,
    34. Masia M,
    35. Matta MA,
    36. Miro O,
    37. Murdoch DR,
    38. Nuermberger E,
    39. Paolini R,
    40. Perello R,
    41. Snijders D,
    42. Plecko V,
    43. Sorde R,
    44. Stralin K,
    45. van der Eerden MM,
    46. Vila-Corcoles A,
    47. Watt JP
    . 2013. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One8(4):e60273. doi:10.1371/journal.pone.0060273.
    OpenUrlCrossRef
  19. 19.↵
    1. Musher DM,
    2. Alexandraki I,
    3. Graviss EA,
    4. Yanbeiy N,
    5. Eid A,
    6. Inderias LA,
    7. Phan HM,
    8. Solomon E
    . 2000. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore)79:210–221. doi:10.1097/00005792-200007000-00002.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Albrich WC,
    2. Madhi SA,
    3. Adrian PV,
    4. van Niekerk N,
    5. Mareletsi T,
    6. Cutland C,
    7. Wong M,
    8. Khoosal M,
    9. Karstaedt A,
    10. Zhao P,
    11. Deatly A,
    12. Sidhu M,
    13. Jansen KU,
    14. Klugman KP
    . 2012. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis54:601–609. doi:10.1093/cid/cir859.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Grijalva CG,
    2. Nuorti JP,
    3. Arbogast PG,
    4. Martin SW,
    5. Edwards KM,
    6. Griffin MR
    . 2007. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U S A: a time-series analysis. Lancet369:1179–1186. doi:10.1016/S0140-6736(07)60564-9.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Bonten MJ,
    2. Huijts SM,
    3. Bolkenbaas M,
    4. Webber C,
    5. Patterson S,
    6. Gault S,
    7. van Werkhoven CH,
    8. van Deursen AM,
    9. Sanders EA,
    10. Verheij TJ,
    11. Patton M,
    12. McDonough A,
    13. Moradoghli-Haftvani A,
    14. Smith H,
    15. Mellelieu T,
    16. Pride MW,
    17. Crowther G,
    18. Schmoele-Thoma B,
    19. Scott DA,
    20. Jansen KU,
    21. Lobatto R,
    22. Oosterman B,
    23. Visser N,
    24. Caspers E,
    25. Smorenburg A,
    26. Emini EA,
    27. Gruber WC,
    28. Grobbee DE
    . 2015. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med372:1114–1125. doi:10.1056/NEJMoa1408544.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Dominguez J,
    2. Blanco S,
    3. Rodrigo C,
    4. Azuara M,
    5. Gali N,
    6. Mainou A,
    7. Esteve A,
    8. Castellvi A,
    9. Prat C,
    10. Matas L,
    11. Ausina V
    . 2003. Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin Microbiol41:2161–2163. doi:10.1128/JCM.41.5.2161-2163.2003.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Boulware DR,
    2. Daley CL,
    3. Merrifield C,
    4. Hopewell PC,
    5. Janoff EN
    . 2007. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect55:300–309. doi:10.1016/j.jinf.2007.06.014.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Stralin K,
    2. Holmberg H
    . 2005. Usefulness of the Streptococcus pneumoniae urinary antigen test in the treatment of community-acquired pneumonia. Clin Infect Dis41:1209–1210. doi:10.1086/444566.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Cremers AJ,
    2. Sprong T,
    3. Schouten JA,
    4. Walraven G,
    5. Hermans PW,
    6. Meis JF,
    7. Ferwerda G
    . 2014. Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. J Antimicrob Chemother69:2258–2264. doi:10.1093/jac/dku109.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Pride MW,
    2. Huijts SM,
    3. Wu K,
    4. Souza V,
    5. Passador S,
    6. Tinder C,
    7. Song E,
    8. Elfassy A,
    9. McNeil L,
    10. Menton R,
    11. French R,
    12. Callahan J,
    13. Webber C,
    14. Gruber WC,
    15. Bonten MJ,
    16. Jansen KU
    . 2012. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol19:1131–1141. doi:10.1128/CVI.00064-12.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Huijts SM,
    2. Pride MW,
    3. Vos JM,
    4. Jansen KU,
    5. Webber C,
    6. Gruber W,
    7. Boersma WG,
    8. Snijders D,
    9. Kluytmans JA,
    10. van der Lee I,
    11. Kuipers BA,
    12. van der Ende A,
    13. Bonten MJ
    . 2013. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J42:1283–1290. doi:10.1183/09031936.00137412.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Grijalva CG,
    2. Wunderink RG,
    3. Zhu Y,
    4. Williams DJ,
    5. Balk R,
    6. Fakhran S,
    7. Courtney DM,
    8. Anderson EJ,
    9. Qi C,
    10. Trabue C,
    11. Pavia AT,
    12. Moore MR,
    13. Jain S,
    14. Edwards KM,
    15. Self WH
    . 2015. In-hospital pneumococcal polysaccharide vaccination is associated with detection of pneumococcal vaccine serotypes in adults hospitalized for community-acquired pneumonia. Open Forum Infect Dis2(4):ofv135. doi:10.1093/ofid/ofv135.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Nzenze SA,
    2. von Gottberg A,
    3. Shiri T,
    4. van Niekerk N,
    5. de Gouveia L,
    6. Violari A,
    7. Nunes MC,
    8. Madhi SA
    . 2015. Temporal changes in pneumococcal colonization in HIV-infected and HIV-uninfected mother-child pairs following transitioning from 7-valent to 13-valent pneumococcal conjugate vaccine, Soweto, South Africa. J Infect Dis212:1082–1092. doi:10.1093/infdis/jiv167.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Rodriguez-Barradas MC,
    2. Tharapel RA,
    3. Groover JE,
    4. Giron KP,
    5. Lacke CE,
    6. Houston ED,
    7. Hamill RJ,
    8. Steinhoff MC,
    9. Musher DM
    . 1997. Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J Infect Dis175:590–597. doi:10.1093/infdis/175.3.590.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Watt JP,
    2. O'Brien KL,
    3. Katz S,
    4. Bronsdon MA,
    5. Elliott J,
    6. Dallas J,
    7. Perilla MJ,
    8. Reid R,
    9. Murrow L,
    10. Facklam R,
    11. Santosham M,
    12. Whitney CG
    . 2004. Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults. J Clin Microbiol42:4974–4976. doi:10.1128/JCM.42.11.4974-4976.2004.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Sinclair A,
    2. Xie X,
    3. Teltscher M,
    4. Dendukuri N
    . 2013. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol51:2303–2310. doi:10.1128/JCM.00137-13.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Murdoch DR,
    2. Laing RT,
    3. Mills GD,
    4. Karalus NC,
    5. Town GI,
    6. Mirrett S,
    7. Reller LB
    . 2001. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol39:3495–3498. doi:10.1128/JCM.39.10.3495-3498.2001.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Stralin K,
    2. Kaltoft MS,
    3. Konradsen HB,
    4. Olcen P,
    5. Holmberg H
    . 2004. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. J Clin Microbiol42:3620–3625. doi:10.1128/JCM.42.8.3620-3625.2004.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Bullowa JGM
    . 1935. The reliability of sputum typing and its relation to serum therapy. JAMA105:1512–1518. doi:10.1001/jama.1935.02760450032007.
    OpenUrlCrossRef
  37. 37.↵
    1. Heffron R,
    2. Varley FM
    . 1932. A study of lobar pneumonia in Massachusetts: methods and results of pneumococcus type determination, 1931-1932. Am J Public Health Nations Health22:1230–1248.
    OpenUrlPubMed
  38. 38.↵
    1. Jain S,
    2. Self WH,
    3. Wunderink RG,
    4. Fakhran S,
    5. Balk R,
    6. Bramley AM,
    7. Reed C,
    8. Grijalva CG,
    9. Anderson EJ,
    10. Courtney DM,
    11. Chappell JD,
    12. Qi C,
    13. Hart EM,
    14. Carroll F,
    15. Trabue C,
    16. Donnelly HK,
    17. Williams DJ,
    18. Zhu Y,
    19. Arnold SR,
    20. Ampofo K,
    21. Waterer GW,
    22. Levine M,
    23. Lindstrom S,
    24. Winchell JM,
    25. Katz JM,
    26. Erdman D,
    27. Schneider E,
    28. Hicks LA,
    29. McCullers JA,
    30. Pavia AT,
    31. Edwards KM,
    32. Finelli L
    . 2015. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med373:415–427.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Jokinen J,
    2. Scott JA
    . 2010. Estimating the proportion of pneumonia attributable to pneumococcus in Kenyan adults: latent class analysis. Epidemiology21:719–725. doi:10.1097/EDE.0b013e3181e4c4d5.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Griffin MR,
    2. Zhu Y,
    3. Moore MR,
    4. Whitney CG,
    5. Grijalva CG
    . 2013. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med369:155–163.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Richter SS,
    2. Heilmann KP,
    3. Dohrn CL,
    4. Riahi F,
    5. Diekema DJ,
    6. Doern GV
    . 2013. Evaluation of pneumococcal serotyping by multiplex PCR and quellung reactions. J Clin Microbiol51:4193–4195.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Brueggemann AB,
    2. Griffiths DT,
    3. Meats E,
    4. Peto T,
    5. Crook DW,
    6. Spratt BG
    . 2003. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis187:1424–1432.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Sleeman KL,
    2. Griffiths D,
    3. Shackley F,
    4. Diggle L,
    5. Gupta S,
    6. Maiden MC,
    7. Moxon ER,
    8. Crook DW,
    9. Peto TE
    . 2006. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis194:682–688. doi:10.1086/505710.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Gray BM,
    2. Converse GM III,
    3. Dillon HC Jr
    . 1980. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis142:923–933.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Andreo F,
    2. Dominguez J,
    3. Ruiz J,
    4. Blanco S,
    5. Arellano E,
    6. Prat C,
    7. Morera J,
    8. Ausina V
    . 2006. Impact of rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults. Respir Med100:884–891. doi:10.1016/j.rmed.2005.08.020.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Huebner RE,
    2. Dagan R,
    3. Porath N,
    4. Wasas AD,
    5. Klugman KP
    . 2000. Lack of utility of serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of different pneumococcal serotypes. Pediatr Infect Dis J19:1017–1020. doi:10.1097/00006454-200010000-00019.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Satzke C,
    2. Dunne EM,
    3. Porter BD,
    4. Klugman KP,
    5. Mulholland EK
    . 2015. The PneuCarriage project: a multi-centre comparative study to identify the best serotyping methods for examining pneumococcal carriage in vaccine evaluation studies. PLoS Med12(11):e1001903. doi:10.1371/journal.pmed.1001903.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Messaoudi M,
    2. Milenkov M,
    3. Albrich WC,
    4. van der Linden MP,
    5. Benet T,
    6. Chou M,
    7. Sylla M,
    8. Barreto Costa P,
    9. Richard N,
    10. Klugman KP,
    11. Endtz HP,
    12. Paranhos-Baccala G,
    13. Telles JN
    . 2016. The relevance of a novel quantitative assay to detect up to 40 major Streptococcus pneumoniae serotypes directly in clinical nasopharyngeal and blood specimens. PLoS One11(3):e0151428. doi:10.1371/journal.pone.0151428.
    OpenUrlCrossRef
  49. 49.↵
    1. Albrich WC,
    2. Madhi SA,
    3. Adrian PV,
    4. van Niekerk N,
    5. Telles JN,
    6. Ebrahim N,
    7. Messaoudi M,
    8. Paranhos-Baccala G,
    9. Giersdorf S,
    10. Vernet G,
    11. Mueller B,
    12. Klugman KP
    . 2014. Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia. BMJ Open4(8):e005953. doi:10.1136/bmjopen-2014-005953.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults
Werner C. Albrich, Michael W. Pride, Shabir A. Madhi, Jan Callahan, Peter V. Adrian, Roger French, Nadia van Niekerk, Shite Sebastian, Victor Souza, Jean-Noel Telles, Glaucia Paranhos-Baccalà, Kathrin U. Jansen, Keith P. Klugman
Journal of Clinical Microbiology Dec 2016, 55 (1) 302-312; DOI: 10.1128/JCM.01573-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults
Werner C. Albrich, Michael W. Pride, Shabir A. Madhi, Jan Callahan, Peter V. Adrian, Roger French, Nadia van Niekerk, Shite Sebastian, Victor Souza, Jean-Noel Telles, Glaucia Paranhos-Baccalà, Kathrin U. Jansen, Keith P. Klugman
Journal of Clinical Microbiology Dec 2016, 55 (1) 302-312; DOI: 10.1128/JCM.01573-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antigens, Bacterial
HIV Infections
immunoassay
Pneumonia, Pneumococcal
Streptococcus pneumoniae
diagnosis
human immunodeficiency virus
pneumococcal pneumonia
serotyping
urinary antigen

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X